These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30391577)

  • 1. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
    Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY
    J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
    J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
    Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
    Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer.
    Zschaeck S; Li Y; Bütof R; Lili C; Hua W; Troost ECG; Beck M; Amthauer H; Kaul D; Kotzerke J; Baur ADJ; Ghadjar P; Baumann M; Krause M; Hofheinz F
    Int J Cancer; 2020 Sep; 147(5):1427-1436. PubMed ID: 32010957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
    J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between prognosis and lymph node status using
    Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
    World J Surg; 2024 Mar; 48(3):650-661. PubMed ID: 38686781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of
    Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
    J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of
    Hamai Y; Hihara J; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Aoki Y; Furukawa T; Okada M
    Ann Surg Oncol; 2019 Jun; 26(6):1869-1878. PubMed ID: 30675704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer.
    Jingu K; Umezawa R; Yamamoto T; Takeda K; Ishikawa Y; Takahashi N; Kadoya N; Matsushita H
    Int J Clin Oncol; 2019 Aug; 24(8):927-933. PubMed ID: 30863993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer.
    Makino T; Yamasaki M; Tanaka K; Tatsumi M; Takiguchi S; Hatazawa J; Mori M; Doki Y
    Surgery; 2017 Oct; 162(4):836-845. PubMed ID: 28711321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Huang TC; Lin CC; Wu YC; Chia-Hsien Cheng J; Lee JM; Wang HP; Huang PM; Hsu FM; Yeh KH; Cheng AL; Tzen KY; Hsu CH
    J Formos Med Assoc; 2019 Jun; 118(6):1024-1030. PubMed ID: 30502100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
    Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
    BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
    zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
    J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.